Table 2. Patient and tumor characteristics.

Patient	Age [y]	Menopause status	Histologic type	Histological grading	B classification	MIB-1 [%]	Receptor status			Molecular subtype
							ER	PR	HER2
1	65	Post	IDC	2	5b	10	+	+	–	Luminal A
2	54	Peri	IDC	3	5b	30	+	–	–	Luminal A
3	39	Pre	IDC	2	5b	40	+	+	+	Luminal B
4	66	Post	IDC	2	5b	60	+	+	–	Luminal A
5	50	Pre	IDC	3	5b	50	+	+	+	Luminal B
6	73	Post	IDC	3	5b	20	+	+	–	Luminal A
7	76	Post	IDC	2	5b	20	+	+	–	Luminal A
8	63	Post	IDC	3	5	30	+	+	–	Luminal A
9	48	Post	IDC	3	5b	20	+	+	+	Luminal B
10	58	Post	IDC	1	5c	20	+	+	+	Luminal B
11	61	Post	IDC	3	5b	70	–	–	–	Triple negative
12	52	Pre	ILC	n.s.	5b	50	+	+	–	Luminal A
13	42	Pre	IDC	3	5b	80	+	–	–	Luminal A
14	67	Post	IDC	3	5b	40	+	+	–	Luminal A
15	61	Post	ILC	2	5b	30	+	+	–	Luminal A
16	41	Pre	Mucinous	2	5b	50	+	+	+	Luminal B

MIB-1: mindbomb E3 ubiquitin protein ligase 1 (proliferative activity), IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor 2, n.s.: not specified.